About Rachel Jimenez, MD
Dr. Jimenez is an Associate Professor of Radiation Oncology at Harvard Medical School (HMS), a radiation oncologist in the Department of Radiation Oncology at Massachusetts General Hospital, and the Editor-in-Chief of Advances in Radiation Oncology. She holds an AB from Harvard University, an MD from Harvard Medical School, and completed her residency and chief residency training in the Harvard Radiation Oncology Program. She has also completed a Fellowship at HMS in Medical Ethics.
Her clinical practice focuses on treatment of patients with breast cancer. She has special expertise in the use of proton radiation and the reduction of cardiac toxicity. She has also advanced the development of a tattoo-free treatment approach for women with breast cancer and has pursued research to optimize quality of life outcomes after radiotherapy. Dr. Jimenez is nationally recognized in the field of Radiation Oncology for the treatment of breast cancer. Her research has informed consensus guidelines and she has made novel contributions, specifically in the role of proton beam therapy for patients with breast cancer. She is the recipient of independent grant funding through the American Society of Clinical Oncology (ASCO), the American Cancer Society and The Greenwall Foundation. She serves as the Principal Investigator of multiple clinical trials exploring the prevention of cardiac toxicity after breast radiotherapy.
She lectures nationally and internationally and serves on multiple national committees in Oncology including within the cooperative groups (NRG Oncology – Breast Locoregional Subcommittee, Alliance for Oncology in Clinical Trials – Ethics Committee, ASCO Ethics Committee - Chair), and professional societies (ASTRO, ASCO, ABR). She also serves on patient advocacy organizations including survivingbreastcancer.org (SBC). Dr. Jimenez is an honoree for the MGH Cancer Center's "The One Hundred," a recipient of the Partners in Excellence Outstanding Patient Care Award, the MGH Patient Experience Award, and the BRIDGE Award honoring providers who promote equity in patient care. She is a recipient of the MGH Claflin Distinguished Scholar Award and is also a repeat nominee for the Brian A. McGovern Award for Clinical Excellence.
Clinical Interests:
- Breast Cancer
- Proton Beam Therapy
- Proton radiation for breast cancer
- Proton radiation therapy
- Proton therapy
Treats:
- Adult
Locations
Mass General Cancer Center: Radiation Oncology
55 Fruit St.
Lunder Building, LL3
Boston, MA 02114
Phone: 617-726-4090
Medical Education
- MD, Harvard Medical School*
- Residency, Brigham and Women's Hospital
American Board Certifications
- Radiation Oncology, American Board of Radiology
Accepted Insurance Plans
- Aetna
- Beech Street
- Blue Cross Blue Shield
- Blue Cross Blue Shield Medicare
- Blue Cross Blue Shield NH
- Cigna
- Commonwealth Care Alliance
- Coventry
- Fallon Health
- Harvard Pilgrim Health Care
- Humana
- Maine Community Health Options
- Mass General Brigham Health Plan
- MassHealth
- Medicaid CT
- Medicaid ME
- Medicaid NH
- Medicaid RI
- Medicaid VT
- Medicare
- Medicare - NH
- Medicare ACO
- Multiplan
- NH Healthy Families
- Railroad Medicare
- Senior Whole Health
- TriCare
- Tufts Health Plan
- United Health Care
- Wellpoint
- WellSense
- WellSense NH
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Reviews: Comments and Ratings
Patient Gateway
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
Adolescent and Young Adult (AYA) Cancer Program
The Adolescent and Young Adult Cancer Program was created to optimize the care, outcomes, and experiences of adolescent and young adult patients.
A Top Hospital in America
Mass General is recognized as a top hospital on the U.S. News Best Hospitals Honor Roll for 2024-2025.
Leaders in Proton Therapy
Mass General has the only proton therapy site in all of New England, with two proton therapy centers.